利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

138 条记录 (耗时 0.027 秒)

    Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level
    42.
    发明授权
    Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level 有权
    根据其sB7H6血清水平治疗胃肠肉瘤患者的方法

    公开(公告)号：US09557333B2

    公开(公告)日：2017-01-31

    申请号：US14429789

    申请日：2013-09-20

    申请人： INSTITUT GUSTAVE ROUSSY ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

    发明人： Eric Vivier ,  Laurence Zitvogel

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57438 ,  G01N33/57407 ,  G01N33/57446 ,  G01N2333/70532 ,  G01N2333/70539 ,  G01N2500/10 ,  G01N2800/52

    摘要： The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, a method of selecting an appropriate chemotherapeutic treatment of cancer, a method of screening or identifying a compound suitable for improving the treatment of a cancer, and corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and, when the expression level is determined, a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.

    摘要翻译： 本发明涉及一种预测或监测具有肿瘤的受试者对化疗的敏感性的方法，选择适合的癌症化学治疗的方法，筛选或鉴定适于改善癌症治疗的化合物的方法 ，以及相应的套件。 预测或监测具有肿瘤的受试者对化疗的敏感性的方法通常包括以下步骤：a）在来自所述受试者的生物样品中测定可溶性B7H6中的至少一种的存在，不存在或表达水平（ sB7H6或sB7-H6）和可溶性MIC（sMIC），并且当确定表达水平时，将步骤b）比较所述表达水平与参考表达水平，从而评估或监测是否具有肿瘤的受试者是响应性的或 耐化学疗法。

    Prognostic marker for myeloproliferative neoplasms
    49.
    发明授权
    Prognostic marker for myeloproliferative neoplasms 有权

    公开(公告)号：US11732303B2

    公开(公告)日：2023-08-22

    申请号：US15739454

    申请日：2016-06-24

    申请人： Institut Gustave-Roussy

    发明人： Christine Bellane-Chantelot ,  Isabelle Plo ,  William Vainchenker ,  Cécile Saint-Martin ,  Antonio D Di Stefano ,  Joseph Saliba

    IPC分类号： C12Q1/6886 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  G01N33/57426 ,  C12Q2600/156

    摘要： The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.